Estimating the Final Price of a Prescription Medicine

To estimate the final price of a prescription medicine in Germany, you start from the manufacturer selling price (Herstellerabgabepreis, ApU), add the regulated wholesale mark-up and pharmacy mark-up set by the Arzneimittelpreisverordnung (AMPreisV), then add 19 percent VAT. That produces the pharmacy retail price. It does not produce what anyone actually pays, because statutory rebates, reimbursement amounts, discount contracts, reference price ceilings and patient co-payment all sit on top of that arithmetic.

The calculation itself is not difficult. Every step is codified, and the same formula applies to every pharmacy in the country. What makes drug price estimation in Germany unreliable is not the maths. It is the assumptions you make before you start calculating: which price you took as your input, whether the product sits inside a negotiated reimbursement regime, whether a discount contract applies to the specific patient, and whether a reference price caps the whole thing.

This article walks one example all the way through, then works backwards through the four assumptions that most often make a confident-looking estimate wrong.

Which price are you starting from?

The single most common source of error is beginning with the wrong number. German pharmaceutical pricing uses several distinct prices, and they are not interchangeable.

If you take an AVP from a product listing and treat it as a manufacturer price, your estimate will be inflated by roughly a third. If you take a list ApU for a product that has been through a benefit assessment, you may be using a number that has been superseded by a negotiated reimbursement amount. Getting the input level right is worth more than any refinement further down the chain.

The regulated wholesale mark-up

For prescription medicines dispensed through pharmacies, wholesale remuneration is fixed by law rather than by negotiation. Under section 2 of the Arzneimittelpreisverordnung, wholesalers charge a fixed amount of 73 cents per package plus a percentage component of at most 3.15 percent of the ApU, and that percentage component is capped at 37.80 EUR.

Two consequences matter for estimation. First, the percentage element is a ceiling, not a floor: a wholesaler may grant part of it back to the pharmacy as a purchasing discount, so the AEP a pharmacy actually pays can be below the calculated maximum. Second, because of the 37.80 EUR cap, the wholesale mark-up stops growing on high-value products. For a specialty medicine with a five-figure ApU, wholesale remuneration is a rounding error, which is exactly why direct supply models exist for that part of the market.

The pharmacy mark-up

Section 3 AMPreisV sets the pharmacy mark-up for prescription-only finished medicinal products as a percentage plus a fixed fee per package. As of 1 July 2026 the components are: 3 percent of the pharmacy purchase price, plus a fixed 9.00 EUR per dispensed package, plus 21 cents towards the emergency service fund, plus 20 cents to finance additional pharmaceutical services under section 129(5e) SGB V.

The fixed fee dominates. On a mid-priced package, the flat 9.00 EUR is several times the percentage element, which is the deliberate design of the German system: pharmacy remuneration is largely decoupled from the value of the goods. Note that the fixed component is scheduled to rise again to 9.50 EUR on 1 January 2027, so any estimate carries a date stamp whether you write one or not.

VAT

Germany applies the standard VAT rate of 19 percent to medicinal products, including prescription medicines. There is no reduced rate for pharmaceuticals, which is unusual in European comparison and adds meaningfully to the gross retail price. VAT is applied to the net retail price after both mark-ups.

The worked example, end to end

Take a prescription-only finished medicinal product with a manufacturer selling price of 50.00 EUR, dispensed to a patient covered by statutory health insurance, with no reference price and no discount contract in force. The figures below follow the structure published by ABDA in its official example calculation.

Read the two bold lines together. The shelf price is 75.32 EUR. The payer bears 62.52 EUR. The manufacturer, having listed at 50.00 EUR, receives 46.50 EUR after the statutory rebate. Three different and equally defensible answers to the question "what does this medicine cost", and this is the simple case, with none of the complications below in play.

The rebates that sit outside the mark-up chain

Two deductions in the table are not part of the price build-up at all. They are transfers back to the payer, and they are the first thing a naive calculation omits.

• The pharmacy rebate (Apothekenabschlag) under section 130 SGB V is a fixed amount per prescription-only package dispensed at the expense of statutory health insurance. The statutory base amount is 1.77 EUR. It was temporarily raised to 2.00 EUR from 1 February 2023 to 31 January 2025 under the GKV-Finanzstabilisierungsgesetz, and that time limit has since expired. A further increase to 2.07 EUR has been legislated to take effect on 1 January 2027. If you are reading an older worked example, check which of these three numbers it used and when it was written.
• Statutory manufacturer rebates under section 130a SGB V are layered. The general rebate is 7 percent of the ApU. Patent-free, substitutable products carry an additional generics rebate. A separate price moratorium clause claws back price increases measured against a 2009 baseline, adjusted annually for consumer price inflation. Which of these apply to a given product is a property of the product, not of the calculation.

Where AMNOG replaces your starting number

For a medicine with a new active substance, the manufacturer sets the price freely at launch. After the early benefit assessment, a reimbursement amount is negotiated under section 130b SGB V and replaces the free price as the basis for reimbursement.

This creates the single largest estimation trap in the German market. A product can carry a list price that is materially above the negotiated reimbursement amount, and the arithmetic above will happily run on either. The negotiated discount itself is not published as a discount, only the resulting amount is visible, and only from the date it takes effect.

"I cannot see by how much the price was reduced in the course of the negotiations." Consultant, health economics (translated from German)

Practically, this means an estimate for an AMNOG product needs a date and a status: free-priced launch phase, or post-negotiation. Getting that wrong is not a rounding error, it is a different price regime.

Discount contracts and reference prices: the patient-specific layer

Two further mechanisms mean that the "price" of a substitutable medicine is not a single number even on the same day in the same pharmacy.

Rabattverträge are selective discount agreements between an individual sickness fund and an individual manufacturer. The pharmacy is generally obliged to dispense the contracted product for a patient insured with that fund. The discount is confidential and is not visible in list price data. The consequence for estimation is uncomfortable but unavoidable: for a substitutable molecule, the effective price depends on which fund the patient belongs to, and no publicly derived figure will capture it.

Festbeträge, the reference price ceilings set under section 35 SGB V, cap what statutory health insurance will reimburse for a group of comparable products. If a product is priced above its reference price, the fund pays the reference amount and the patient pays the difference on top of the normal co-payment. Manufacturers therefore tend to price at or below the ceiling, which is why reference price groups show heavy price clustering rather than a spread.

Patient co-payment under section 61 SGB V is 10 percent of the retail price with a floor of 5.00 EUR and a ceiling of 10.00 EUR, and never more than the cost of the product itself. Products priced at least 30 percent below their reference price may be exempted from co-payment entirely.

A checklist for a defensible estimate

Before presenting a number, confirm each of the following. Every one of them can move the answer by more than the entire pharmacy mark-up.

1. Price level. Is your input an ApU, an AEP or an AVP? Label it explicitly.
2. Validity date. German prices change on a twice-monthly cadence, on the 1st and the 15th. An estimate without a date is an estimate without a value.
3. AMNOG status. Free-priced launch phase, or a negotiated reimbursement amount in force?
4. Reference price. Is the product in a Festbetrag group, and is it priced at, below or above the ceiling?
5. Discount contract. Is the molecule substitutable and under contract? If so, state clearly that the payer-side effective price cannot be derived from list data.
6. Rebate profile. Which of the section 130a rebates apply, including the generics rebate and the price moratorium?
7. Perspective. Are you answering for the patient, the pharmacy, the payer or the manufacturer? These are four different numbers from one calculation.

Why this is a data problem more than a maths problem

Everything above is deterministic once the inputs are known. The difficulty is that the inputs live in different places: article master data and prices per PZN, benefit assessment status and reimbursement amounts, reference price group membership, substitution eligibility, and the historical price series you need if you want to reconstruct what a price was on a past date rather than today.

Assembling that per product, per date, by hand is where estimation projects stall. pharmazie.com maintains these layers together, with the German article master data and price history alongside 25+ pharmaceutical databases, covering 50,000+ German products and 120,000+ international products across 50+ countries, accessible through the platform or through API and webservice integration into ERP and merchandise management systems. For price reconstruction and cross-border comparison in particular, that consolidation is the difference between a defensible figure and an educated guess.

This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.